Evidence map›Paper›PMID 41023733›Full record

ArticleBMC medicine2025

Gaps in the global health research landscape for mpox: an analysis of research activities and existing evidence.

Rodrigo Furst, Emilia Antonio, Marieke de Swart, Isabel Foster, Johannes Paolo Cerrado, Zaharat Kadri-Alabi, Susan Khader Ibrahim, Lauren Ashley, Duduzile Ndwandwe, Louise Sigfrid and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rodrigo FurstPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Emilia AntonioPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Marieke de SwartPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Isabel FosterGloPID-R Research and Policy Team, Policy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Johannes Paolo CerradoPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Zaharat Kadri-AlabiPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Susan Khader IbrahimPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Lauren AshleyPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Duduzile NdwandweCochrane South Africa, South African Medical Research Council, Cape Town, South Africa.
Louise SigfridPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Alice NortonPolicy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK. alice.norton@ndm.ox.ac.uk.

Funding

International Development Research Centre 109910-001National Institute for Health and Care Research CSA2022GloPID-R-3387UK Research and Innovation 10061268Wellcome TrustWellcome Trust 226543
6 · The paper itself

Abstract

backgroundSince December 2022, human cases of mpox in the Democratic Republic of the Congo (DRC) have risen at unprecedented rates. We identified a need for systematic mapping of the active research landscape and evidence, assessing their alignment with both local and global research priorities, to inform urgently needed research investments to support response efforts.

methodsWe conducted a mapping review of global research funding and international clinical trial registries and established a systematic rapid research needs appraisals platform to identify existing evidence gaps on mpox research. We analysed the alignment of these to established research categories and both local and globally identified mpox-specific research priorities.

resultsWe identified 124 ongoing mpox research grants, 79 registered trials and 415 published studies. Most grants (85.0%, n = 105/124), clinical trials (49.3%, n = 39/79) and primary studies (57.7%, n = 205/355) were conducted in high-income countries, with most evidence published in response to the 2022 clade II global mpox outbreaks. Research funding has been focussed on vaccine and therapeutic pre-clinical development. Key gaps remain in both ongoing research and evidence relating to clinical characterisation among populations at risk, clinical trials on effective medical countermeasures specific to clade I, social sciences, health systems research, and healthcare and community protection.

conclusionsOur findings highlight persistent research gaps related to mpox clade Ib, particularly the limited knowledge on its characteristics and a lack of ongoing efforts to develop effective medical countermeasures, posing a risk to control efforts. Aligning research and investments to locally and globally identified research priorities and evidence gaps will help support national, regional and international responses to prevent transmission and improve outcomes.

Indexed as

Biomedical ResearchGlobal HealthMpox, MonkeypoxClinical Trials as TopicDemocratic Republic of the CongoEvidence GapsHumansMpoxResearch fundingResearch gapsResearch prioritisation

Identifiers

PMID41023733
PMCPMC12482760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.